OUR STORY

CellTherX was founded to augment and enhance regenerative medicine and specifically the wound healing process that occurs in acute and chronic wounds. The lack of technological advancements in the acellular dermal matrices (ADM) and xenografts marketplace has placed a spotlight on CellTherX’s mission to differentiate itself with its proprietary Microsurfacing technology.

 CellTherX’s intellectual property includes method, process, and apparatus patents that improve the efficacy of currently utilized smooth surface reconstructive grafts by a process called Micro-surfacing. The processes are applicable to, but not limited to, acellular dermal, split thickness skin, and decellularized amnion/chorion tissue.

Micro-surfacing of tissue grafts increases the surface area of the graft and thereby promotes the graft-to-host cellular interaction and the adhesion of the graft, which results in reduced time of healing. Maximizing the surface area of regenerative grafts is key to faster proliferation and an improved seal at the wound-to-host interface.  

In addition to CellTheX’s products and processes for regenerative tissue grafts; the company is developing novel interventions in the fields of cell and gene therapies applied to regenerative wound healing.